CLS Americas and HALO Diagnostics Initiate Prostate Cancer Clinical Study using TRANBERG Focal Laser Ablation System

Minimally Invasive, Outpatient Treatment Provides High Precision Laser Focal Therapy of Prostate Tumors in an ASC

LOS ANGELES, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems Americas, Inc. (CLS), a leading provider of office-based, focal laser ablation (FLA) systems for urologists, and HALO Diagnostics, a leader in precision diagnostics and image-guided therapies (HALO Dx), today announced a 25-patient clinical study using the TRANBERG Thermal Therapy System to perform image-guided focal laser ablation (FLA) of low-to-intermediate risk prostate cancer in patients. Data from these patients treated over the next 6-8 months will be entered into the patient registry where their long-term follow up will be monitored and conducted. The CLS TRANBERG System provides safe and effective focal laser ablation of low-to-medium risk prostate tumors, while also preserving healthy tissue to minimize the risk of unwanted side effects such as ED and urinary incontinence.

In the US, over one million prostate biopsies are performed every year leading to a diagnosis of prostate cancer for almost 250,000 men. Focal laser ablation of prostate tumors has demonstrated high levels of precision and accuracy with low risk of side effects, such as erectile dysfunction and urinary incontinence.

“CLS is pleased to collaborate with Dr. Scionti and HALO Diagnostics for this clinically significant study regarding the efficacy of treating prostate cancer using image-guided focal laser ablation in an ASC,” stated Michael Magnani, president of CLS Americas. “We look forward to providing clinical support and collaborative assistance to Dr. Scionti with the new TRANBERG treatment. This study is a continuation of our long-standing collaborative research with HALO and will contribute further evidence to support the precise cancer control and quality of life benefits offered by FLA.”

“Image-guided focal laser ablation of low-to-intermediate risk prostate cancer has the potential to provide improved quality of life benefits over other types of treatments,” stated Dr. Stephen Scionti, founder and director of the Scionti Prostate Center. “HALO Diagnostic is excited to begin this clinically significant study with CLS Americas and to begin offering this safe and minimally invasive procedure with the new TRANBERG laser through our network.”